Health science marketing and communications firm, SCORR Marketing, has released the results of its Global Trends Survey Report, which is focused on the health science industry.
A new paper from EEF is urging the government to set out clear guidance on the rules of engagement for industry sector deals ahead of the release of the Industrial Strategy White Paper, to minimise the impact of Brexit on supply chains.
Allison Gilpin, business unit manager, global serialisation and Ray Hook, manager global serialisation services, PCI Pharma Services, discuss the impact of serialisation requirements on packaging operations.
In the third episode of our series, we talk to Richard Limb who is the new head of Quality Assurance at one of the UK’s independent suppliers of both Specials and clinical trial medicines to healthcare professionals, Nova Laboratories.
With serialisation efforts in full swing connecting the dots across the full supply chain is becoming important. Here, Christophe Devins and Chuck Sailer, Adents, explain why Level 4 serialisation is uniquely positioned for data sharing.
A recent partnership to address the challenge of monitoring adherence in ophthalmic clinical trials was formed between Aptar Pharma and Kali Care. Here, Sina Fateh and Sai Shankar discuss this alliance further.
Speed to market is a significant concern in tablet manufacturing, however, moving too quickly may cause problems. Here, Dr Charles Kettler and Robert Sedlock reveal anticipatory experiments to help make the transition from R&D to full scale smooth.
Drug discovery and development company, AiCuris, has been granted fast track designation by the US FDA for oral pritelivir — its lead candidate for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised adults.
A recent study from Zebra Technologies has revealed that manufacturers are investing in wearable technologies to eliminate pen and paper from supply chains
CPhI Worldwide, organised by UBM, have announced the panel for the 2017 Annual Industry Report, which will represent the fifth edition. As such, a decision has been made to review the past five years’ reports to see how accurate the predictions were.
Focusing on the keys to success for contract drug manufacturers, Arnaud Sergent, Serge Hovsepian, Nohmie Ben Rekassa and Ben Faircloth from L.E.K. Consulting detail the differentiation strategies that have proven themselves in the marketplace
R&D efficiency has been in decline for many years, but now with bodies, like the FDA, aiming to accelerate approval times and a critical need for new therapies to combat antibiotic resistant strains of bacteria will we see the tide turn?
